

research updates**Medical Marijuana: Spring 1997 Overview. 3****Rick Doblin****LSD Research at Orenda Institute. 4****Richard Yensen, Ph.D. and Donna Dryer, M.D., M.P.H.****Lecturing about Ketamine Psychedelic Therapy in the United States. 5****Evgeny Krupitsky, M.D., Ph.D.****conference reports****The Entheobotany Conference—San Francisco, October 1996. 6****Robert Segal****International Conference on Ecstasy—Bologna, Italy, November 1996. 10****Marianne D'Amore****1997 BPC Seminar on Ethnobotany—Palenque, Mexico, January 1997. 13****Kate Chapman****in print and on television****Psychoalytic and Psychedelic Therapy 1931-1995: A Bibliographical Perspective. 18****Torsten Passie, M.D., M.A.****On the crest of a wave: BBC's Psychedelic Science. 20****Simon G. Powell, comments by Karl Jansen, M.D., Ph.D.****MAPS Membership and Renewal Information. 22****F E A T U R E D I N T H E N E X T M A P S B U L L E T I N :****Interview with Dr. Albert Hofmann****Mini-Reviews of Non-English Publications by Jonathan Ott**

While we can be grateful that there is again considerable publishing activity on the subject of shamanic inebriants in the United States many books are being published in languages other than English, scarcely coming to the attention of aficionados in this country.

Book reviews by June Riedlinger, R.Ph., Pharm.D.

Two recent books by Michael Montagne and co-authors present valuable information on the drug discovery, development, and approval process in the U.S., which has great implications for the future therapeutic use of psychedelic drugs.

Reports on a March 1997 European workshop on hallucinogenic drugs in experimental psychiatric research, *The Role of MAOIs in the Hallucinogenic Experience* by John H. Halpern, M.D., and much more...

ISSN 1080-8981

MAPS (Multidisciplinary Association for Psychedelic Studies) is a membership-based organization working to assist psychedelic researchers around the world design, obtain governmental approval, fund, conduct and report on psychedelic research in humans. Founded in 1986, MAPS is an IRS approved 501 (c)(3) non-profit corporation funded by tax deductible donations. MAPS has previously funded basic scientific research into the safety of MDMA (3,4, methylenedioxyamphetamine, *Ecstasy*) and has opened a Drug Master File for MDMA at the U.S. Food and Drug Administration. MAPS is now focused primarily on assisting scientists to conduct human studies to generate essential information about the risks and psychotherapeutic benefits of MDMA, other psychedelics, and marijuana, with the goal of eventually gaining government approval for their medical uses. Interested parties wishing to copy any portion of this newsletter are encouraged to do so and are kindly requested to credit MAPS including name and address. The MAPS newsletter is produced by a small group of dedicated staff and volunteers. Your participation, financial or otherwise, is welcome. © 1996 Multidisciplinary Association for Psychedelic Studies, Inc. (MAPS) 1801 Tippah Avenue, Charlotte, NC 28205. Phone: (704) 358-9830. Fax: (704) 358-1650. Internet: Info@maps.org, and <http://www.maps.org>